Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts.

Takahashi M, Miki S, Fujimoto K, Fukuoka K, Matsushita Y, Maida Y, Yasukawa M, Hayashi M, Shinkyo R, Kikuchi K, Mukasa A, Nishikawa R, Tamura K, Narita Y, Hamada A, Masutomi K, Ichimura K.

Cancer Sci. 2019 Jul;110(7):2247-2257. doi: 10.1111/cas.14067. Epub 2019 Jun 10.

2.

Semi-quantitative Detection of RNA-dependent RNA Polymerase Activity of Human Telomerase Reverse Transcriptase Protein.

Maida Y, Yasukawa M, Ghilotti M, Ando Y, Masutomi K.

J Vis Exp. 2018 Jun 12;(136). doi: 10.3791/57021.

3.

Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma.

Miki S, Imamichi S, Fujimori H, Tomiyama A, Fujimoto K, Satomi K, Matsushita Y, Matsuzaki S, Takahashi M, Ishikawa E, Yamamoto T, Matsumura A, Mukasa A, Nishikawa R, Masutomi K, Narita Y, Masutani M, Ichimura K.

Cancer Sci. 2018 Jul;109(7):2275-2285. doi: 10.1111/cas.13637. Epub 2018 Jun 19.

4.

Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.

Masui K, Komori T, Kato Y, Masutomi K, Ichimura K, Ogasawara S, Kaneko MK, Oki H, Suzuki H, Nitta M, Maruyama T, Muragaki Y, Kawamata T, Sawada T, Shibata N.

Biomed Res Int. 2018 Mar 5;2018:7945845. doi: 10.1155/2018/7945845. eCollection 2018.

5.

ATF7 mediates TNF-α-induced telomere shortening.

Maekawa T, Liu B, Nakai D, Yoshida K, Nakamura KI, Yasukawa M, Koike M, Takubo K, Chatton B, Ishikawa F, Masutomi K, Ishii S.

Nucleic Acids Res. 2018 May 18;46(9):4487-4504. doi: 10.1093/nar/gky155.

6.

Room Temperature Decarboxylative and Oxidative [2+2+2] Annulation of Benzoic Acids with Alkynes Catalyzed by an Electron-Deficient Rhodium(III) Complex.

Honjo Y, Shibata Y, Kudo E, Namba T, Masutomi K, Tanaka K.

Chemistry. 2018 Jan 9;24(2):317-321. doi: 10.1002/chem.201703928. Epub 2017 Oct 26.

PMID:
28944514
7.

Rhodium-Catalyzed Asymmetric [2 + 2 + 2] Cyclization of 1,6-Enynes with Aliphatic and Aromatic Alkenes.

Ueda H, Masutomi K, Shibata Y, Tanaka K.

Org Lett. 2017 Jun 2;19(11):2913-2916. doi: 10.1021/acs.orglett.7b01149. Epub 2017 May 22.

PMID:
28530409
8.

CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors.

Ishibashi M, Neri S, Hashimoto H, Miyashita T, Yoshida T, Nakamura Y, Udagawa H, Kirita K, Matsumoto S, Umemura S, Yoh K, Niho S, Tsuboi M, Masutomi K, Goto K, Ochiai A, Ishii G.

Sci Rep. 2017 Apr 21;7:46662. doi: 10.1038/srep46662.

9.

A novel method to generate single-cell-derived cancer-associated fibroblast clones.

Hashimoto H, Suda Y, Miyashita T, Ochiai A, Tsuboi M, Masutomi K, Kiyono T, Ishii G.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1409-1419. doi: 10.1007/s00432-017-2409-3. Epub 2017 Mar 31.

PMID:
28364361
10.

Asymmetric Synthesis of Protected Cyclohexenylamines and Cyclohexenols by Rhodium-Catalyzed [2+2+2] Cycloaddition.

Masutomi K, Sugiyama H, Uekusa H, Shibata Y, Tanaka K.

Angew Chem Int Ed Engl. 2016 Dec 5;55(49):15373-15376. doi: 10.1002/anie.201608952. Epub 2016 Nov 10.

PMID:
27860088
11.

Oxidative Annulation of Arenecarboxylic and Acrylic Acids with Alkynes under Ambient Conditions Catalyzed by an Electron-Deficient Rhodium(III) Complex.

Kudo E, Shibata Y, Yamazaki M, Masutomi K, Miyauchi Y, Fukui M, Sugiyama H, Uekusa H, Satoh T, Miura M, Tanaka K.

Chemistry. 2016 Sep 26;22(40):14190-4. doi: 10.1002/chem.201603499. Epub 2016 Aug 17.

PMID:
27459131
12.

Clonal heterogeneity in osteogenic potential of lung cancer-associated fibroblasts: promotional effect of osteogenic progenitor cells on cancer cell migration.

Suda Y, Neri S, Hashimoto H, Higuchi Y, Ishibashi M, Sugano M, Masutomi K, Tsuboi M, Ochiai A, Ishii G.

J Cancer Res Clin Oncol. 2016 Jul;142(7):1487-98. doi: 10.1007/s00432-016-2171-y. Epub 2016 Apr 27.

PMID:
27119516
13.

De Novo RNA Synthesis by RNA-Dependent RNA Polymerase Activity of Telomerase Reverse Transcriptase.

Maida Y, Yasukawa M, Masutomi K.

Mol Cell Biol. 2016 Mar 31;36(8):1248-59. doi: 10.1128/MCB.01021-15. Print 2016 Apr.

14.

Rhodium-Catalyzed Asymmetric [2 + 2 + 2] Cycloaddition of 1,6-Enynes with Cyclopropylideneacetamides.

Yoshizaki S, Nakamura Y, Masutomi K, Yoshida T, Noguchi K, Shibata Y, Tanaka K.

Org Lett. 2016 Feb 5;18(3):388-91. doi: 10.1021/acs.orglett.5b03387. Epub 2016 Jan 12.

PMID:
26756430
15.

Sound segregation via embedded repetition is robust to inattention.

Masutomi K, Barascud N, Kashino M, McDermott JH, Chait M.

J Exp Psychol Hum Percept Perform. 2016 Mar;42(3):386-400. doi: 10.1037/xhp0000147. Epub 2015 Oct 19.

16.

Cancer cell invasion driven by extracellular matrix remodeling is dependent on the properties of cancer-associated fibroblasts.

Neri S, Hashimoto H, Kii H, Watanabe H, Masutomi K, Kuwata T, Date H, Tsuboi M, Goto K, Ochiai A, Ishii G.

J Cancer Res Clin Oncol. 2016 Feb;142(2):437-46. doi: 10.1007/s00432-015-2046-7. Epub 2015 Sep 15.

PMID:
26374424
17.

Telomerase reverse transcriptase moonlights: Therapeutic targets beyond telomerase.

Maida Y, Masutomi K.

Cancer Sci. 2015 Nov;106(11):1486-92. doi: 10.1111/cas.12806. Epub 2015 Oct 21. Review.

18.

Rhodium-Catalyzed [3+2+2] and [2+2+2] Cycloadditions of Two Alkynes with Cyclopropylideneacetamides.

Yoshida T, Tajima Y, Kobayashi M, Masutomi K, Noguchi K, Tanaka K.

Angew Chem Int Ed Engl. 2015 Jul 6;54(28):8241-4. doi: 10.1002/anie.201502505. Epub 2015 Jun 1.

PMID:
26032593
19.

Telomerase reverse transcriptase regulates microRNAs.

Lassmann T, Maida Y, Tomaru Y, Yasukawa M, Ando Y, Kojima M, Kasim V, Simon C, Daub CO, Carninci P, Hayashizaki Y, Masutomi K.

Int J Mol Sci. 2015 Jan 6;16(1):1192-208. doi: 10.3390/ijms16011192.

20.

Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells.

Yamaguchi S, Maida Y, Yasukawa M, Kato T, Yoshida M, Masutomi K.

PLoS One. 2014 Nov 6;9(11):e112438. doi: 10.1371/journal.pone.0112438. eCollection 2014.

21.

Enantioselective cycloisomerization of 1,6-enynes to bicyclo[3.1.0]hexanes catalyzed by rhodium and benzoic acid.

Masutomi K, Noguchi K, Tanaka K.

J Am Chem Soc. 2014 May 28;136(21):7627-30. doi: 10.1021/ja504048u. Epub 2014 May 16.

PMID:
24823870
22.

Nucleostemin expression in invasive breast cancer.

Kobayashi T, Masutomi K, Tamura K, Moriya T, Yamasaki T, Fujiwara Y, Takahashi S, Yamamoto J, Tsuda H.

BMC Cancer. 2014 Mar 21;14:215. doi: 10.1186/1471-2407-14-215.

23.

Involvement of telomerase reverse transcriptase in heterochromatin maintenance.

Maida Y, Yasukawa M, Okamoto N, Ohka S, Kinoshita K, Totoki Y, Ito TK, Minamino T, Nakamura H, Yamaguchi S, Shibata T, Masutomi K.

Mol Cell Biol. 2014 May;34(9):1576-93. doi: 10.1128/MCB.00093-14. Epub 2014 Feb 18.

24.

Frequency-change aftereffect produced by adaptation to real and illusory unidirectional frequency sweeps.

Masutomi K, Kashino M.

J Acoust Soc Am. 2013 Jul;134(1):EL14-8. doi: 10.1121/1.4807304.

PMID:
23862900
25.

Off-target effect of endogenous siRNA derived from RMRP in human cells.

Maida Y, Kyo S, Lassmann T, Hayashizaki Y, Masutomi K.

Int J Mol Sci. 2013 Apr 29;14(5):9305-18. doi: 10.3390/ijms14059305.

26.

Rhodium-catalyzed regio-, diastereo-, and enantioselective [2+2+2] cycloaddition of 1,6-enynes with acrylamides.

Masutomi K, Sakiyama N, Noguchi K, Tanaka K.

Angew Chem Int Ed Engl. 2012 Dec 21;51(52):13031-5. doi: 10.1002/anie.201206122. Epub 2012 Nov 19.

PMID:
23161833
27.

Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.

Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M, Yonemori K, Shimizu C, Ando M, Masutomi K, Yoshida T, Fujiwara Y, Tamura K.

Cancer Sci. 2012 Sep;103(9):1665-71. doi: 10.1111/j.1349-7006.2012.02359.x. Epub 2012 Aug 1.

28.

All-trans retinal mediates light-induced oxidation in single living rod photoreceptors.

Masutomi K, Chen C, Nakatani K, Koutalos Y.

Photochem Photobiol. 2012 Nov-Dec;88(6):1356-61. doi: 10.1111/j.1751-1097.2012.01129.x. Epub 2012 Mar 28.

29.

Kinetics of DNA replication and telomerase reaction at a single-seeded telomere in human cells.

Hirai Y, Masutomi K, Ishikawa F.

Genes Cells. 2012 Mar;17(3):186-204. doi: 10.1111/j.1365-2443.2012.01581.x.

30.

Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for esophageal carcinoma.

Nakajima TE, Yoshida H, Okamoto N, Nagashima K, Taniguchi H, Yamada Y, Shimoda T, Masutomi K.

Cancer Sci. 2012 Feb;103(2):233-8. doi: 10.1111/j.1349-7006.2011.02142.x. Epub 2011 Dec 8.

31.

RMRP is a non-coding RNA essential for early murine development.

Rosenbluh J, Nijhawan D, Chen Z, Wong KK, Masutomi K, Hahn WC.

PLoS One. 2011;6(10):e26270. doi: 10.1371/journal.pone.0026270. Epub 2011 Oct 19.

32.

Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells.

Jinushi M, Chiba S, Yoshiyama H, Masutomi K, Kinoshita I, Dosaka-Akita H, Yagita H, Takaoka A, Tahara H.

Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12425-30. doi: 10.1073/pnas.1106645108. Epub 2011 Jul 11.

33.

Maintenance of tumor initiating cells of defined genetic composition by nucleostemin.

Okamoto N, Yasukawa M, Nguyen C, Kasim V, Maida Y, Possemato R, Shibata T, Ligon KL, Fukami K, Hahn WC, Masutomi K.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20388-93. doi: 10.1073/pnas.1015171108. Epub 2011 Jul 5.

34.

Comparison of telomere length and association with progenitor cell markers in lacrimal gland between Sjögren syndrome and non-Sjögren syndrome dry eye patients.

Kawashima M, Kawakita T, Maida Y, Kamoi M, Ogawa Y, Shimmura S, Masutomi K, Tsubota K.

Mol Vis. 2011;17:1397-404. Epub 2011 May 27.

35.

Two-step cleavage of hairpin RNA with 5' overhangs by human DICER.

Ando Y, Maida Y, Morinaga A, Burroughs AM, Kimura R, Chiba J, Suzuki H, Masutomi K, Hayashizaki Y.

BMC Mol Biol. 2011 Feb 9;12:6. doi: 10.1186/1471-2199-12-6.

36.

RNA-dependent RNA polymerases in RNA silencing.

Maida Y, Masutomi K.

Biol Chem. 2011 Apr;392(4):299-304. doi: 10.1515/BC.2011.035. Epub 2011 Feb 7. Review.

PMID:
21294682
37.

An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA.

Maida Y, Yasukawa M, Furuuchi M, Lassmann T, Possemato R, Okamoto N, Kasim V, Hayashizaki Y, Hahn WC, Masutomi K.

Nature. 2009 Sep 10;461(7261):230-5. doi: 10.1038/nature08283. Epub 2009 Aug 23.

38.

Suppression of hPOT1 in diploid human cells results in an hTERT-dependent alteration of telomere length dynamics.

Possemato R, Timmons JC, Bauerlein EL, Wada N, Baldwin A, Masutomi K, Hahn WC.

Mol Cancer Res. 2008 Oct;6(10):1582-93. doi: 10.1158/1541-7786.MCR-08-0070.

39.

A non-canonical function of zebrafish telomerase reverse transcriptase is required for developmental hematopoiesis.

Imamura S, Uchiyama J, Koshimizu E, Hanai J, Raftopoulou C, Murphey RD, Bayliss PE, Imai Y, Burns CE, Masutomi K, Gagos S, Zon LI, Roberts TM, Kishi S.

PLoS One. 2008;3(10):e3364. doi: 10.1371/journal.pone.0003364. Epub 2008 Oct 10.

40.

High Twist expression is involved in infiltrative endometrial cancer and affects patient survival.

Kyo S, Sakaguchi J, Ohno S, Mizumoto Y, Maida Y, Hashimoto M, Nakamura M, Takakura M, Nakajima M, Masutomi K, Inoue M.

Hum Pathol. 2006 Apr;37(4):431-8.

PMID:
16564917
41.

Efficient inhibition of human telomerase reverse transcriptase expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy.

Nakamura M, Masutomi K, Kyo S, Hashimoto M, Maida Y, Kanaya T, Tanaka M, Hahn WC, Inoue M.

Hum Gene Ther. 2005 Jul;16(7):859-68.

PMID:
16000067
42.

The telomerase reverse transcriptase regulates chromatin state and DNA damage responses.

Masutomi K, Possemato R, Wong JM, Currier JL, Tothova Z, Manola JB, Ganesan S, Lansdorp PM, Collins K, Hahn WC.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8222-7. Epub 2005 May 31.

43.

Analysis of telomeric single-strand overhang length in human endometrial cancers.

Hashimoto M, Kyo S, Masutomi K, Maida Y, Sakaguchi J, Mizumoto Y, Nakamura M, Hahn WC, Inoue M.

FEBS Lett. 2005 May 23;579(13):2959-64.

44.

Telomerase: regulation, function and transformation.

Dong CK, Masutomi K, Hahn WC.

Crit Rev Oncol Hematol. 2005 May;54(2):85-93. Review.

PMID:
15843091
45.

Nucleolin interacts with telomerase.

Khurts S, Masutomi K, Delgermaa L, Arai K, Oishi N, Mizuno H, Hayashi N, Hahn WC, Murakami S.

J Biol Chem. 2004 Dec 3;279(49):51508-15. Epub 2004 Sep 14.

46.

Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling.

Satyanarayana A, Greenberg RA, Schaetzlein S, Buer J, Masutomi K, Hahn WC, Zimmermann S, Martens U, Manns MP, Rudolph KL.

Mol Cell Biol. 2004 Jun;24(12):5459-74.

47.

A Bacillus thuringiensis crystal protein with selective cytocidal action to human cells.

Ito A, Sasaguri Y, Kitada S, Kusaka Y, Kuwano K, Masutomi K, Mizuki E, Akao T, Ohba M.

J Biol Chem. 2004 May 14;279(20):21282-6. Epub 2004 Mar 16.

48.

Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.

Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia Z, Anderson KS, Hahn WC, Nadler LM.

Clin Cancer Res. 2004 Feb 1;10(3):828-39.

49.

Telomerase expression--only half the story.

Masutomi K, Hahn WC.

Cancer Biol Ther. 2003 Nov-Dec;2(6):685-6. No abstract available.

PMID:
14688477
50.

Significance of immunological detection of human telomerase reverse transcriptase: re-evaluation of expression and localization of human telomerase reverse transcriptase.

Kyo S, Masutomi K, Maida Y, Kanaya T, Yatabe N, Nakamura M, Tanaka M, Takarada M, Sugawara I, Murakami S, Taira T, Inoue M.

Am J Pathol. 2003 Sep;163(3):859-67.

Supplemental Content

Loading ...
Support Center